NATCO Pharma has addressed queries regarding recent news items, confirming its plans to launch Semaglutide in India in March 2026, following CDSCO approval on February 14, 2026. The company stated that its partnership with Eris Lifesciences Ltd for this product is routine business with no material financial impact. Furthermore, NATCO confirmed awareness of no undisclosed information that could explain unusual trading activity prior to this announcement.
Response to Stock Exchange Queries
NATCO Pharma Limited has issued a clarification in response to a letter concerning a news item published on livemint.com. The company addressed specific points raised regarding ongoing negotiations and trading activity preceding this disclosure.
Semaglutide Launch and Partnerships
In response to whether negotiations were taking place, NATCO confirmed that it is actively working with several marketing partners to launch its Semaglutide product in the Indian market during March 2026. This timeline follows the receipt of approval from the Central Drugs Standard Control Organisation (CDSCO) on February 14, 2026. The company specifically noted that the partnership established with Eris Lifesciences Ltd for this product falls within the ordinary course of business and is not expected to have a material impact on the company’s operations.
Trading Movement Disclosure
When questioned about awareness of any unpublished price-sensitive information that could explain recent movements in the company’s trading, NATCO explicitly stated: “No”. The company confirmed it has consistently adhered to all disclosure requirements concerning material information.
Material Impact Assessment
Regarding the potential financial impact of the article being discussed, NATCO confirmed that, as of the date of this communication, there is no material financial impact stemming from the article on the company.
Source: BSE
